Illumina Launches Enhanced Cancer Research Assay with Built-in HRD Detection and Faster Results

SAN DIEGO– Illumina Inc. (NASDAQ: ILMN) has unveiled an upgraded version of its flagship cancer research tool, the TruSight Oncology 500 (TSO 500 v2), designed to accelerate access to comprehensive tumor profiling through improved workflow efficiency, lower tissue requirements, and integrated biomarker analysis.

The new assay now includes built-in detection of homologous recombination deficiency (HRD), powered by Myriad Genetics’ Genomic Instability Score (GIS) algorithm, at no additional cost. TSO 500 v2 enables labs to assess hundreds of genes and immuno-oncology biomarkers from a small tissue sample, streamlining cancer research for therapy selection and clinical trial eligibility.

“TSO 500 is a trusted assay used by hundreds of researchers worldwide, and these enhancements deliver even greater value,” said Everett Cunningham, Illumina’s Chief Commercial Officer. “The improved workflow helps labs perform comprehensive genomic profiling more efficiently and at scale, ultimately broadening access to critical tumor profiling.”

Key improvements in TSO 500 v2 include:

• Faster turnaround time and reduced hands-on processing

• Improved variant detection, especially in challenging genomic regions

• HRD status included for all samples using the Myriad® GIS algorithm

• Sustainable packaging with fewer components and color-coded tubes for ease of use

• Integrated analysis pipeline, including DRAGEN™ secondary analysis and compatibility with third-party tools like Velsera’s Clinical Genomics Workspace

• Broad compatibility with high- and mid-throughput Illumina sequencers

Early-access users have praised the enhancements. Dr. Weiyi Chen of siParadigm Diagnostic Informatics reported improved data accuracy and workflow efficiency. Dr. Conxi Lázaro of the Catalan Institute of Oncology noted the simplified packaging and setup made lab operations faster and more accurate.

The TSO 500 v2 is part of Illumina’s broader oncology portfolio, which supports both research and clinical applications, reinforcing the company’s commitment to advancing precision cancer care through scalable, high-quality genomic solutions.